One of the hotter areas of cancer drug research involves using a particular type of bispecific antibody as the backbone for therapeutic combinations intended to bring a multi-pronged attack to tumors.

Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 11 Most Active Small Cap Stocks to Buy. On March 18, CytomX Therapeutics ...

Akari Therapeutics Plc (NASDAQ:AKTX) said its research has been selected for presentation at the American Association for ...

ArriVent Biopharma, a company that secures rights to drugs from emerging markets to develop them for Western markets, is adding to its pipeline with a Phase 1-ready drug candidate from China that has ...

VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, ...

Catalent gains global rights to evaluate certepetide and its analogs for use as SMARTag ® payloads across multiple ADCs designed to address difficult-to-treat diseases Catalent’s preclinical study ...

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its plans to ...

Merck (MRK) and its Japanese partner Daiichi Sankyo announced that the FDA has granted Breakthrough Therapy Designation ("BTD") to their investigational pipeline candidate, raludotatug deruxtecan ...